Full coverage· Health· Updated
Wegovy Trial Shows Significant Weight Loss in Children Aged 6-12
A global trial of the weight-loss drug Wegovy in children aged 6-12 showed significant BMI reduction, with over 40% achieving normal weight after 68 weeks. The drug's safety profile in children was found to be similar to adults, with common side effects like nausea and constipation.
1 newsroom · 1 language · since
Plus
What happened
- 01Wegovy trial shows significant weight loss in children aged 6-12.
- 02Over 40% of child participants achieved normal weight after 68 weeks.
- 0316 Israeli children participated in the international study.
- 04Drug's safety in children mirrors that seen in adults.
- 05Hope expressed for inclusion in Israel's health basket.
The coverage
One newsroom on this story
Who covered it
Only N12 so far. No other newsroom has reported it yet.
